Get the Stockscreener App
1.486
1.32%
-0.024
Pepgen Inc stock is traded at $1.486, with a volume of 60,436.
It is down -1.32% in the last 24 hours and down -3.25% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
See More
Previous Close:
$1.51
Open:
$1.52
24h Volume:
60,436
Relative Volume:
0.04
Market Cap:
$102.72M
Revenue:
-
Net Income/Loss:
$-89.66M
P/E Ratio:
-0.6139
EPS:
-2.4205
Net Cash Flow:
$-81.90M
1W Performance:
+7.97%
1M Performance:
-3.25%
6M Performance:
-75.53%
1Y Performance:
+2.05%
1-Day Range:
$1.4706
$1.56
1-Week Range:
$1.37
$1.595
52-Week Range:
$1.01
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.485 | 104.45M | 0 | -89.66M | -81.90M | -2.4205 |
VRTX
Vertex Pharmaceuticals Inc
|
435.62 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
640.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.86 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.89 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.09 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | Guggenheim | Buy |
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
[EFFECT] PepGen Inc. SEC Filing - Stock Titan
PEPG Stock Price, Quote & Chart | PEPGEN INC (NASDAQ:PEPG) - ChartMill
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program - BioSpace
PepGen’s PGN-EDODM1 Shows Promising Safety and Efficacy in Myotonic Dystrophy Type 1 Clinical Trials – FREEDOM2 Study Update - Minichart
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting - PharmiWeb.com
PepGen unveils new PGN-EDODM1 clinical data at IDMC-15 - Traders Union
PepGen Highlights DM1 Program Progress in Updated Presentation - TipRanks
H.C. Wainwright reiterates PepGen stock rating on data outlook - Investing.com
PepGen updates corporate presentation, highlights FREEDOM2 milestones and PGN-EDODM1 data - TradingView
PepGen (NASDAQ: PEPG) details DM1 trial data and cash runway outlook - Stock Titan
H.C. Wainwright reiterates PepGen stock rating on data outlook By Investing.com - Investing.com Canada
PepGen (PEPG) loses 14.3% in 4 weeks, here's why a trend reversal may be around the corner - MSN
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance Singapore
PepGen files to offer up to $400 mln in securities from time to time - marketscreener.com
PepGen Files To Offer Up To $400 Mln In Securities From Time To Time - TradingView
According to documents submitted to the SEC, biotechnology company PepGen Inc. has signed a new sales agreement, which will completely replace the company's previous sales arrangement. - Bitget
PepGen (NASDAQ: PEPG) ups capital flexibility with $400M shelf and $100M ATM - Stock Titan
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now? - Insider Monkey
Why is PepGen stock sinking Tuesday? - MSN
PepGen (PEPG) upgraded to buy: Here's what you should know - MSN
Viking Global reports 3.48M shares in PepGen (NASDAQ: PEPG) - Stock Titan
[SCHEDULE 13G/A] PepGen Inc. Amended Passive Investment Disclosure - Stock Titan
TradingKey - TradingKey
Wedbush Maintains PepGen(PEPG.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
PepGen Inc. Stock 12‑Month Price Target Cut to $10, Implies 495% Upside - TradingView
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Wedbush Trims Price Target on PepGen to $4 From $5, Maintains Outperform Rating - marketscreener.com
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - BioSpace
PepGen: $132.3M of Cash as of March 31 Sufficient to Fund Ops Through FREEDOM2 12.5 Mg/kg MAD Readout and Into 2H 2027 >PEPG - Moomoo
First quarter 2026 financial results released as PepGen announces new corporate developments - Traders Union
PepGen Q1 loss narrows as operating expenses fall - TradingView
PepGen (PEPG) posts Q1 2026 loss, updates FREEDOM2-DM1 trial and FDA hold - Stock Titan
PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
PepGen (NASDAQ: PEPG) cuts Q1 2026 loss as cash reaches $132.3M - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - ACCESS Newswire
MSN Money - MSN
PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PepGen Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Pictet Asset Management Holding SA Purchases 871,059 Shares of PepGen, Inc. $PEPG - MarketBeat
PepGen falls 20% despite earnings beat on FDA hold concerns By Investing.com - Investing.com Nigeria
PepGen crashes after mid-stage trial data for muscle disorder therapy - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - FinancialContent
[ARS] PepGen Inc. SEC Filing - Stock Titan
PepGen (NASDAQ: PEPG) details 2026 virtual meeting and auditor vote - Stock Titan
PepGen advances momentum with Palo Alto meeting on DM1 community engagement - Traders Union
PepGen shares slide 20% as FDA clinical hold overshadows earnings beat - MSN
Wedbush Maintains PepGen (PEPG) Outperform Recommendation - MSN
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):